NCT02419742 2022-10-12
Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen
Hoffmann-La Roche
Phase 4 Completed
Clinical Trials
11 trialsNCT04031885 2021-08-24
A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer
Eli Lilly and Company
Phase 4 Terminated
NCT02445586 2019-10-29
Safety Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in Indian Participants With Breast Cancer
Hoffmann-La Roche
Phase 4 Completed
NCT01094184 2018-03-22
BATMAN
Hoffmann-La Roche
Phase 4 Completed
NCT02088515 2017-03-03
Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 4 Completed
NCT01665417 2017-02-08
Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma
Betta Pharmaceuticals Co., Ltd.
Phase 4 Unknown
NCT00774241 2016-11-02
PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer
Hoffmann-La Roche
Phase 4 Withdrawn
NCT00536107 2013-10-01
Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
AstraZeneca
Phase 4 Terminated
NCT00127933 2011-08-10
XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
Hoffmann-La Roche
Phase 4 Completed
NCT00280098 2009-12-07
Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
Sanofi
Phase 4 Completed
NCT00772681 2009-12-07
Tax-Nazo
Sanofi
Phase 4 Completed